Rhythm Pharmaceuticals, Inc.
RYTM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.37 | 1.63 | -0.05 | 0.13 |
| FCF Yield | -3.34% | -5.14% | -11.71% | -30.59% |
| EV / EBITDA | -15.04 | -15.39 | -7.99 | -6.40 |
| Quality | ||||
| ROIC | -95.53% | -66.44% | -52.18% | -59.32% |
| Gross Margin | 89.73% | 87.99% | 90.98% | 81.01% |
| Cash Conversion Ratio | 0.44 | 0.74 | 0.96 | 2.10 |
| Growth | ||||
| Revenue 3-Year CAGR | 76.57% | 190.63% | – | – |
| Free Cash Flow Growth | 16.39% | 23.36% | -17.35% | -23.93% |
| Safety | ||||
| Net Debt / EBITDA | -0.70 | 0.35 | 0.72 | 0.83 |
| Interest Coverage | -12.89 | -13.27 | -34.45 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.71 | 1.08 | 0.73 | 5.40 |
| Cash Conversion Cycle | 227.03 | 216.80 | -225.60 | -3,309.58 |